Department of Quality Management, Birmingham VA Medical Center, Birmingham, AL 35294, USA.
Sex Transm Dis. 2012 Aug;39(8):645-7. doi: 10.1097/OLQ.0b013e3182536574.
Serologic tests for syphilis results at the time of diagnosis are the basis for evaluating response to syphilis therapy. After treatment, however, serologic tests for syphilis titers may continue to increase for several weeks. We evaluated rapid plasma reagin (RPR) titer variation during the 14 days after therapy using data from a recent large, prospective randomized controlled trial.
Prospectively enrolled participants in North America and Madagascar with primary, secondary, or early latent syphilis were randomly assigned to penicillin, doxycycline (in the case of penicillin allergy), or azithromycin treatment. Blood for RPR analysis was drawn at days 0, 7, and 14 posttreatment. All RPR titers were determined simultaneously at a central laboratory.
Four hundred and seventy patients had data available for at least 2 of 3 RPR measurements. Overall, 20% of patients showed a titer increase of at least 1 dilution in the 14 days after therapy. The greatest proportion of titer increases following therapy was observed in patients with primary syphilis. Comparing outcome of therapy using the initial (day 0) RPR titer versus the maximal RPR titer (during 14 days) resulted in outcome reclassification in 2.98% of participants.
Despite the fact that about 20% of early syphilis patients had increases in RPR titers immediately after treatment, these changes rarely influenced assessment of therapeutic outcome. Only 3% of patients treated would have been reclassified.
在诊断时进行的梅毒血清学检测结果是评估梅毒治疗反应的基础。然而,在治疗后,梅毒血清学滴度检测可能会在数周内持续升高。我们使用最近一项大型前瞻性随机对照试验的数据评估了治疗后 14 天内快速血浆反应素(RPR)滴度的变化。
在北美和马达加斯加,患有一期、二期或早期潜伏梅毒的参与者被前瞻性地随机分配接受青霉素、强力霉素(青霉素过敏时)或阿奇霉素治疗。在治疗后第 0、7 和 14 天采集血液进行 RPR 分析。所有 RPR 滴度均在中央实验室同时进行检测。
470 名患者至少有 3 次 RPR 测量中的 2 次数据可用。总体而言,20%的患者在治疗后 14 天内出现至少 1 个稀释度的滴度升高。在治疗后滴度升高比例最大的是原发性梅毒患者。与初始(第 0 天)RPR 滴度相比,使用治疗期间的最大 RPR 滴度(14 天内)来评估治疗结果,导致 2.98%的参与者重新分类。
尽管约 20%的早期梅毒患者在治疗后立即出现 RPR 滴度升高,但这些变化很少影响对治疗结果的评估。仅有 3%的接受治疗的患者会被重新分类。